Association of Helicobacter pylori with central serous chorioretinopathy: Hypotheses regarding pathogenesis

Medical Hypotheses

Volumn 63, Issue 3, 2004, Pages 524-527

  Giusti, Cristiano ^a,b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b Italy ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE;

ANTIBIOTIC THERAPY; ANTIGEN EXPRESSION; CENTRAL SEROUS RETINOPATHY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FIBRINOLYSIS; GENETIC PREDISPOSITION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HYPOTHESIS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PIGMENT EPITHELIUM; PREVALENCE; PRIORITY JOURNAL; RETINA DETACHMENT; REVIEW; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL IMPAIRMENT;

BACTERIA (MICROORGANISMS); HELICOBACTER; HELICOBACTER PYLORI;

EID: 3342898465     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.02.020     Document Type: Article

References (24)

1. Albert D.M., Jakobiec F.A. Principles and practice of ophthalmology. 1994;Saunders, Philadelphia
2. Iida T., Yannuzzi L.A., Spaide R.F., et al. Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina. 23:2003;1-7
3. Teschner S., Noack J., Birngruber R., Schmidt-Erfurth U. Characterization of leakage activity in exudative chorioretinal disease with three-dimensional confocal angiography. Ophthalmology. 110:2003;687-697
4. Yannuzzi L.A., Slakter J.S., Gross N.E., et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 23:2003;288-298
5. Kitaya N., Nagaoka T., Hikichi T., et al. Features of abnormal choroidal circulation in central serous chorioretinopathy. Br. J. Ophthalmol. 87:2003;709-712
6. Prunte C., Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am. J. Ophthalmol. 121:1996;26-34
7. Iijima H., Iida T., Murayama K., et al. Plasminogen activator inhibitor 1 in central serous chorioretinopathy. Am. J. Ophthalmol. 127:1999;477-478
8. Michael J.C., Pak J., Pulido J., de Venecia G. Central serous chorioretinopathy associated with administration of sympathomimetic agents. Am. J. Ophthalmol. 136:2003;182-185
9. Carvalho-Recchia C.A., Yannuzzi L.A., Negrao S., et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology. 109:2002;1834-1837
10. Giusti C. Central serous chorioretinopathy: a new extragastric manifestation of Helicobacter pylori? Analysis of a clinical case. Clin. Ter. 152:2001;393-397
11. Mauget-Faÿsse M., Kodjikian L., Quaranta M., et al. Rôle de l'Helicobacter pylori dans la choriorétinopathie séreuse centrale et l'épithéliopathie rétinienne diffuse. Résultats de la première étude prospective pilote. J. Fr. Ophthalmol. 25:2002;1021-1025
12. Franceschi F., Sepulveda A.R., Gasbarrini A., et al. Cross-reactivity of anti-CagA antibodies with vascular wall antigens: possible pathogenic link between Helicobacter pylori infection and atherosclerosis. Circulation. 106:2002;430-434
13. Mayr M., Kiechl S., Mendall M.A., et al. Increased risk of atherosclerosis is confined to CagA-positive Helicobacter pylori strains: prospective results from the Bruneck study. Stroke. 34:2003;610-615
14. Prasad A., Zhu J., Halcox J.P., et al. Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation. 106:2002;184-190
15. Lamb D.J., El-Sankary W., Ferns G.A. Molecular mimicry in atherosclerosis: a role for heat shock proteins in immunisation. Atherosclerosis. 167:2003;177-185
16. Georges J.L., Rupprecht H.J., Blankenberg S., et al. Impact of pathogen burden in patients with coronary artery disease in relation to systemic inflammation and variation in genes encoding cytokines. Am. J. Cardiol. 92:2003;515-521
17. Byrne M.F., Corcoran P.A., Atherton J.C., et al. Stimulation of adhesion molecule expression by Helicobacter pylori and increased neutrophil adhesion to human umbilical vein endothelial cells. FEBS Lett. 532:2002;411-414
18. Byrne M.F., Kerrigan S.W., Corcoran P.A., et al. Helicobacter pylori binds von Willebrand factor and interacts with GPIb to induce platelet aggregation. Gastroenterology. 124:2003;1846-1854
19. Strowski M.Z., Cramer T., Schafer G., et al. Helicobacter pylori stimulates host vascular endothelial growth factor-A (vegf-A) gene expression via MEK/ERK-dependent activation of Sp1 and Sp3. FASEB J. 18:2004;218-220
20. Khairy P., Rinfret S., Tardif J.C., et al. Absence of association between infectious agents and endothelial function in healthy young men. Circulation. 107:2003;1966-1971
21. Neureiter D., Heuschmann P., Stintzing S., et al. Detection of Chlamydia pneumoniae but not of Helicobacter pylori in symptomatic atherosclerotic carotids associated with enhanced serum antibodies, inflammation and apoptosis rate. Atherosclerosis. 168:2003;153-162
22. Wong W.M., Gu Q., Wang W.H., et al. Effects of primary metronidazole and clarithromycin resistance to Helicobacter pylori on omeprazole, metronidazole, and clarithromycin triple-therapy regimen in a region with high rates of metronidazole resistance. Clin. Infect. Dis. 37:2003;882-889
23. Wang W.H., Wong W.M., Dailidiene D., et al. Aspirin inhibits the growth of Helicobacter pylori and enhances its susceptibility to antimicrobial agents. Gut. 52:2003;490-495
24. Jiang Z., Huang A.L., Tao X.H., Wang P.L. Construction and characterization of bivalent vaccine candidate expressing HspA and M(r) 18,000 OMP from Helicobacter pylori. World J. Gastroenterol. 9:2003;1756-1761